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Abstract
Vestibular schwannomas (VS) are a common posterior fossa brain tumor, and though benign can cause significant
morbidity, particularly loss of hearing, tinnitus, vertigo and facial paralysis. The current treatment options for VS include
microsurgical resection, stereotactic radiosurgery or close surveillance monitoring, with each treatment option carrying
associated complications and morbidities. Most importantly, none of these options can definitively reverse hearing loss or
tinnitus. Identification of a novel medical therapy, through the use of targeted molecular inhibition, is therefore a highly
desirable treatment strategy that may minimize complications arising from both tumor and treatment and more
importantly be suitable for patients whose options are limited with respect to surgical or radiosurgical interventions. In this
study we chose to examine the effect of Nilotinib on VS. Nilotinib (TasignaH) is a second-generation receptor tyrosine kinase
(RTK) inhibitor with a target profile similar to that of imatinib (GleevecH), but increased potency, decreased toxicity and
greater cellular and tissue penetration. Nilotinib targets not only the BCR-ABL oncoprotein, but also platelet-derived growth
factor (PDGF) receptor signalling. In this preclinical study, the human NF2-null schwannoma cell line HEI-193 subjected to
nilotinib inhibition demonstrated decreased viability, proliferation and anchorage-independent growth, and increased
apoptosis. A daily dose of nilotinib for 5 days inhibited HEI-I93 proliferation at a clinically-relevant concentration in a dose-
dependent manner (IC50 3–5 mmol/L) in PDGF-stimulated cells. These anti-tumorigenic effects of nilotinib were correlated to
inhibited activation of PDGFR-a and PDGFR-b and major downstream signalling pathways. These experiments support
a therapeutic potential for Nilotinib in VS.
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Introduction
Vestibular schwannomas (VS) are typically slow-growing tumors
that arise from the Schwann cell sheath of the vestibulocochlear
nerve. Though benign, they can cause significant morbidity
through compression of neurologic structures and obstruction of
cerebrospinal fluid flow. Effects on the vestibulocochlear nerve
result in permanent hearing loss, tinnitus and disequilibrium, and
facial nerve compression can cause facial weakness or paralysis
and disfiguration. Symptoms leading to diagnosis occur in 0.7–
1 per 100 000 and are generally unilateral, although in 5–10% of
cases tumors are bilateral and associated with the cancer
predisposition syndrome neurofibromatosis type 2 (NF2). Man-
agement options include observation, surgical excision and
radiosurgery, all of which have significant short- and long-term
adverse effects [1–3]. However, for a distinct population of NF2
patients, surgery and radiosurgery are not feasible and no
additional therapy is currently available.
The tumor suppressor gene NF2, located on chromosome 22 at
22 q12.2, encodes the protein merlin [4], also called schwannomin
[5], an ezrin, moesin and radixin (ERM) family protein that
associates the actin cytoskeleton with the cell membrane [6].
Schwann cell-specific knockout of merlin in mice leads to initiation
of schwannomas [7], likely through loss of inhibition of the AKT
[8] and ERK1/2 [9] signalling pathways. These mediators of
survival and proliferation are activated by cell surface receptors
such as stem cell factor receptor (c-KIT) and platelet-derived
growth factor (PDGF) receptor-a and -b, which are over-expressed
and over-activated in sporadic and NF2-associated peripheral and
vestibular schwannomas [10].
These in vitro studies using the immortalized NF2-null VS cell
line HEI-193 [10] demonstrated that the receptor tyrosine kinase
(RTK) inhibitor imatinib mesylate (Gleevec, STI571) decreased
the activation of c-KIT, PDGFR-a and PDGFR-b, as well as
ERK-1/2, AKT and FAK. Furthermore, imatinib treatment
increased apoptosis and cell cycle arrest, while inhibiting cell
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growth. While developed as an inhibitor of the kinase activity of
the BCR-ABL oncoprotein in chronic myelogenous leukemia
(CML) [11,12], the efficacy of imatinib against other RTKs has led
to its application as a therapy for several human cancers, including
myeloid malignancies [13] and gastrointestinal stromal tumors
[14]. The emergence of imatinib-resistant kinase mutants,
however, warranted the development of new RTK inhibitors.
The compound nilotinib (Tasigna, AMN107) was rationally
designed to improve potency and selectivity over imatinib towards
the BCR-ABL kinase [15]. Nilotinib is also effective against c-
KIT, PDGFR-a, PDGFR-b, and discoidin domain receptor
(DDR) 21 and 22 [16], but has a better toxicity profile [17]
and greater cellular and tissue penetration [18] than imatinib, this
latter consideration of particular significance for chemotherapeutic
agents that must penetrate the blood-brain barrier. Nilotinib is
currently in clinical use for treatment of imatinib-resistant CML
and Philadelphia chromosome-positive acute lymphoblastic leu-
kemia.
In the current study, we chose to investigate the in vitro
therapeutic efficacy of nilotinib in the immortalized human NF2-
null VS cell line HEI-193 in two different growth conditions: in
Schwann cell growth medium (GM) or in media supplemented
with PDGF-BB. We demonstrate that activation of PDGFR-a and
PDGFR-b was inhibited, as well as their downstream mediators
AKT and mTOR. Functional assays demonstrated decreased
viability, proliferation and anchorage-independent growth, and
increased apoptosis, in a dose-dependent manner. Taken together
these results suggest that nilotinib may be a viable option for
treatment of patients with vestibular schwannoma.
Materials and Methods
Nilotinib Treatment
HEI-193 is an HPV E6-E7 immortalized human vestibular
schwannoma cell line (gift from Marco Giovannini and David
Lim: Department of Cell and Molecular Biology, House Ear
Institute, Los Angeles, CA), established after they obtained
informed patient consent [19]. For cell viability, proliferation
and apoptosis experiments, HEI-193 cells were plated at a density
of 1610
3 cells/well in 96-well plates and grown for 24 hours in
DMEM supplemented with 10% FBS. Cultures were then
incubated with vehicle or nilotinib (Novartis, Switzerland) at
concentration 0, 1, 3, 5, 10 or 20 mM for four days in the presence
of one of two growth media: 100 ng/mL PDGF-BB (Cell
Signaling) in DMEM, or Schwann cell growth medium (GM;
[9]) consisting of DMEM, 10% FCS, 0.5 mM forskolin (Sigma),
10 nM b-heregulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX;
Sigma), and 2.5 mg/mL insulin (Sigma). Media containing
nilotinib was refreshed daily, extrapolating from the 18-hour
half-life of nilotinib in human serum. Functional assays were
carried out on the fifth day as described below.
Viability Assays
HEI-193 cells were plated, grown and incubated with nilotinib
as described above. Trypan blue based viable cell counting was
done every day for 5 days, or on the fifth day of nilotinib
treatment, by using the Vi-CELL Coulter Analyzer (Beckman).
The percentage of viable cells is plotted against each dose level and
normalized to HEI-193 cells in PDGF-BB or GM with vehicle
only. Cell viability was also evaluated by the 3-(4,5-dimethyl-
thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium (MTS) assay (CellTiter 96 AQueous Assay System;
Promega) as well as CellTiter-Fluor
TM CelViability Assay
(Promega) according to the manufacturer’s instructions. MTS
labelling reagent was added on the fifth day of nilotinib inhibition,
and the absorbance at 490 nm determined following four hours of
incubation using plate reader (Versa max, Molecular Devices).
CellTiter-Fluor reagent was added for 3 hours on the fifth day of
nilotinib inhibition, and the fluorescence was measured according
to the manufacturing instructions. The mean of six experimental
replicates from three independent experiments was determined for
each nilotinib concentration. Statistical analysis was carried out
using Student’s t-test.
Proliferation Assay
HEI-193 cells were grown and incubated with nilotinib as
described above. On the fourth day of nilotinib inhibition,
bromodeoxyuridine (BrdU) was added to cell cultures and
incubated for the final 18 hours of growth. Cells were fixed and
the ELISA carried out according to the manufacturer’s instruc-
tions (Roche, Switzerland). Sample absorbance was measured at
450 nm. The mean of six experimental replicates from three
independent experiments was determined for each nilotinib
concentration. Statistical analysis was carried out using Student’s
t-test.
Apoptosis Assay
HEI-193 cells were plated, grown and incubated with nilotinib
as described above. Apoptosis was evaluated using the Apo-One
Homogeneous Caspase-3/7 Assay (Promega), with addition of
Apo-One reagent at 5 days following the final dose of nilotinib.
The reagent was incubated for 6 hours and fluorescence measured
according to the manufacturer’s instructions (485 nm excitation/
527 nm emission). The mean of six experimental replicates from
three independent experiments was determined for each nilotinib
concentration. Statistical analysis was carried out using Student’s t-
test.
Cell Cycle Analysis
HEI-193 cells were grown in DMEM supplemented with 10%
FBS for 2 days, serum-starved for 24 hours and then inhibited with
nilotinib (0, 3, 5, 10, or 20 mM) in PDGF-BB or GM for 2 days.
Cell cycle analysis was carried out using propidium iodide (PI; BD
Pharmingen) staining and fluorescence-activated cell sorting
(FACScan; Becton Dickinson). Cells were fixed with 80% ethanol
for 18 hours at 4uC, centrifuged at 1500 rpm, resuspended in
solution containing PI (0.1 mg/mL) and RNaseA (2 mg/mL), and
incubated for 40 minutes at room temperature. Following repeat
centrifugation, cells were resuspended in 500 mL PBS for FACS
analysis. Samples were analyzed using CellQuest Pro (Becton
Dickinson) software. Sub G1, G1, S, G2/M-phase fractions were
calculated as the mean of duplicate experiments.
Soft Agar Clonogenic Assay
Growth media containing 0.5% agar was added to the bottom
of each 60 mm well. HEI-193 cells (1.0610
4) were suspended in
a mixture of 0.35% low-melting point agar (Cambrex), RPMI
1640 and 10% FBS, and plated over solidified base agar. Either
PDGF-BB medium or GM containing vehicle or nilotinib (5, 10 or
20 mM) was added to the agar surface, and changed 5 times per
week. Plates were incubated at 37uC for 3 weeks. Colonies
growing in the agar were stained with 0.005% crystal violet
(Sigma) and visualised using AxioVision (Carl Zeiss, Canada) on
an inverted microscope. Clusters larger than 500 mm were
counted as discrete colonies, and the maximal diameter of colonies
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two independent experiments analyzed by Student’s t-test.
Western Blot Analysis
HEI-193 cells grown in DMEM with 10% FBS to 50%
confluence, then serum-starved for 24 hours. Cells were treated
with vehicle or nilotinib (3, 5, 10 or 20 mM) for 30 minutes or 24
hours, followed by a 10-minute incubation in PDGF-BB medium
or GM in the presence or absence of nilotinib.
Ras-GTP was extracted by applying 600 mg of protein to
glutathione S-transferase-Ras-binding domain of Raf1 (GST-
RBD; Ras Activation Assay Kit, Upstate Biotech). In brief, cells
were lysed in Mg
2+ buffer containing protease (Roche) and
phosphatase (Calbiochem) inhibitors and then incubated for 1
hour at 4uC with glutathione-sepharose beads bound to 6.0 mgo f
GST-RBD. The beads were then washed in lysis buffer, followed
by immunoblotting of the supernatant with the anti-Ras antibody
(1:2000; Upstate Biotech).
Immunoblotting of activated receptor and other downstream
mediators was carried out on whole-cell lysate. In brief, cells
inhibited and stimulated as described above were lysed on ice in
modified PLC lysis buffer supplemented with protease (Roche) and
phosphatase (Calbiochem) inhibitors, and protein concentration
determined using BCA assay. Equal quantities of whole-cell lysate
were separated on 7% SDS-PAGE gel and transferred to PVDF
membrane (NEN) using a semi-dry transfer apparatus (Bio-Rad).
Membranes were probed overnight with activation-specific
phosphotyrosine antibodies to PDGFR-a (Tyr754, Abcam;
1:500), PDGFR-b (Tyr771, Cell Signaling; 1:250), AKT
(Ser473, Cell Signaling; 1:1000), ERK1/2 (Thr202/Tyr204, Cell
Signaling; 1:1000), S6 ribosomal protein (Ser240/244, Cell
Signaling; 1:1000), and mTOR (Ser2448, Cell Signaling;
1:1000). Total protein expression was determined using non–
activation-specific antibodies: PDGFR-a (Cell Signaling; 1:400),
PDGFR-b (Cell Signaling; 1:400), AKT (Cell Signaling; 1:1000),
ERK1/2 (Cell Signaling; 1:1000), S6 ribosomal protein (Cell
Signaling; 1:1000), mTOR (Cell Signaling; 1:1000) and b-actin
(Sigma; 1:20,000). Horseradish peroxidase–conjugated secondary
antibody (Bio-Rad) was used, with visualization carried out using
Chemiluminescence Reagent Plus (Perkin-Elmer). Densitometric
analysis was undertaken to determine the ratio of phosphorylated-
to-total protein levels. The mean ratio of phosphorylated/total
protein as a function of nilotinib dose was analyzed by Student’s t-
test. All densitometric analyses were undertaken within the linear
range with the AlphaEaseFC software. Fold changes were
calculated using the vehicle-containing PDGF- or GM-stimulated
treatment as a standard value of 1.
Results
Optimal Inhibition Conditions
Initial experiments were carried out to establish concentration
of nilotinib which is most tolerated by cells when exposed for
longer duration (Fig. 1). Our results show that 3 mM concentration
of nilotinib was tolerated by cells for at least 5 days before
a significant reduction in viability was observed (1b), and 5 mM for
cells grown in GM. This concentration of nilotinib also happens to
be clinically relevant, below the mean peak inhibitor concentration
(4.27 mM) found in the serum of patients treated for CML [18].
Reduction in Cell Viability and Proliferation
HEI-193 cells grown either in media supplemented with PDGF-
BB or in GM were administered daily doses of nilotinib. The
lowest concentration of nilotinib which resulted in significant
reduction in viable cells for PDGF-BB condition after 5 days
treatment, was determined to be 3 mM, by two separate assays,
MTS (Fig. 2A) and fluorescent based viability assay (Fig. 2B).
Higher concentrations did not provide additional advantage in
terms of decreased cell viability except very high (20 mM)
concentration of nilotinib.
Decrease in cell viability is also reflected by significant and
concomitant decrease in proliferating cells upon treatment with
3 mM nilotinib for 5 days (Fig. 2C). For the cell cultured in GM
conditions, a higher nilotinib concentration (5 mM) is effective for
significant decrease in cell viability (as shown by two separate
assays; Fig. 2A and B) and proliferation (Fig. 2C). A further
decrease in viability and proliferation was observed at higher
concentrations of nilotinib.
As shown in Fig. 1A and B, cells cultured in PDGF-BB
conditions and exposed to 3 mM concentrations of nilotinib was
well tolerated for longer time as compared to 20 mM, as well as
5 mM for cells grown in GM (data not shown and Fig. 1c).
Nilotinib thus decreased cell viability and proliferation in a manner
that is dependent upon drug concentration as well as growth
conditions.
Increase in Caspase-dependent Apoptosis
As determined by caspase-3/7 activity assay normalized ratio to
cell number, nilotinib induced apoptosis in HEI-193 in a dose-
dependent manner. In cultures grown in media containing PDGF-
BB, in the presence of $3 mM nilotinib, caspase-3/7 activity was
significantly increased (p,0.005) at 5 days following the final
inhibitor dose (Fig. 3a). When cells grown in GM were assayed for
caspase-3/7 activity at 5 days following the final nilotinib dose, an
increase in apoptosis (p,0.005) was observed at $5 mM nilotinib
compared to vehicle (Fig. 3a).
Induction of Cell Cycle Arrest
To explore the cell cycle status of cells treated with nilotinib,
concentration and duration of exposure was selected where control
and treated cells were phenotypically comparable (3 mM for 2 days
in PDGF and 5 mM for 2 days in GM conditions). Measurement
of propidium iodide (PI) staining demonstrated a significant
increase (p,0.05) in the number of cells in G1 phase following 2
days of nilotinib treatment (Fig. 3b). For cells grown in PDGF-BB,
this increase was observed in the presence of $3 mM nilotinib with
no further increase at higher concentrations. This increase in G1
was accompanied by a reduction in the number of cells in S-phase,
as well as reduction in the G2/M cycle. An increase in the number
of cells in G1 phase, with a corresponding reduction in G2/M-
phase cells, was observed in the presence of $5 mM nilotinib for
cells grown in GM (Fig. 3c), with not statistically changes in the S-
phase.
Reduction in Anchorage-independent Growth
HEI-193 cells treated with nilotinib showed a dose-dependent
decrease in the number and size of colonies formed in soft agar
(Fig. 4a). Cells grown in PDGF-BB formed fewer (Fig. 4b) and
smaller (Fig. 4c) colonies in $3 mM nilotinib, compared to vehicle.
In GM, the presence of $5 mM nilotinib reduced the total
number (Fig. 4b) of colonies formed, as well as their diameter
(Fig. 4c).
Reduced Activation of Targeted Receptors
HEI-193 cells were pre-treated for 30 minutes with nilotinib of
different concentrations prior to stimulation with PDGF-BB or
GM. Quantification of phosphorylation-specific immunoblot
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PDGF-BB stimulation for 10 minutes resulted in high activation of
the PDGFR-a and PDGFR-b receptors (Fig. 5a). Stimulation with
GM activated PDGFR-b (Fig. 5b); however, phosphorylation of
PDGFR-a did not increase above baseline (data not shown). A
significant decrease in receptor activation was seen with both
PDGF-BB and GM stimulation at nilotinib concentration as low
as 3 mM. The expression for total PDGFR-a and PDGFR-
b receptors decreased upon stimulation with PDGF-BB, likely due
to rapid receptor endocytosis kinetics upon ligand binding.
Inhibition of Downstream Mediators
HEI-193 cells were pre-incubated with nilotinib for 24 hours
then stimulated with PDGF-BB or GM for 10 minutes. The
Figure 1. Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. (A) HEI-193 grown in
(PDGF or GM) were treated with 0, 3 or 20 mM nilotinib. Phase contrast microscopy images obtained at 1, 2 and 5 days show fewer cells with
increasing nilotinib concentration. Scale bar =500 mm. (B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 mM nilotinib up to 5 days.
Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 mM nilotinib, compared to vehicle shown, mean and SD of six
technical replicates. **denotes significant (p,0.005) difference between treated and untreated samples. (C) HEI-193 grown in GM were treated with
0, 3, 5 or 20 mM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 5 mM nilotinib. Shown, mean
and SD of six technical replicates. **denotes significant (p,0.005) difference between treated and untreated samples.
doi:10.1371/journal.pone.0039412.g001
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193 cells in a dose-dependent manner. HEI-193 cells grown in
PDGF-BB or GM were evaluated after 5 days of treatment with 0, 3, 5, 10
or 20 mM nilotinib. Shown, mean value of six technical replicates.
*denotes significant value (p,0.05), **denotes significant value
(p,0.005) (A) Nilotinib decreased absorbance on MTS viability assay
in both growth conditions. (B) Compared to cells grown in vehicle
control, nilotinib reduced the absorbance on fluorescence viability
assay in both growth conditions. (c) Proliferation measured by BrdU
incorporation was decreased by nilotinib in both growth conditions.
doi:10.1371/journal.pone.0039412.g002
Figure 3. Nilotinib induces apoptosis and cell cycle arrest in
HEI-193 cells at clinically-relevant concentrations. (A) HEI-193
cells were treated with 0, 3, 5, 10 or 20 mM nilotinib for 5 days. In PDGF-
BB, an increase in caspase-3/7 activity is seen at $3 mM; in GM, caspase-
3/7 activity is increased at $5 mM. Fluorescence signal normalized to
number of viable cells. Shown, mean value of six technical replicates. (B)
HEI-193 cells were treated with 0, 3, 5, 10 or 20 mM nilotinib for 2 days.
Nilotinib Efficacy in Vestibular Schwannoma Cells
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39412addition of either PDGF-BB or GM resulted in activation of
effectors involved in multiple pro-tumorigenic pathways, including
Ras, AKT, mTOR, and S6 ribosomal protein (Fig. 6a, b). In
PDGF-BB media, Nilotinib was effective, in inhibiting activation
of AKT at 3 mM, of Ras and mTOR at 5 mM nilotinib. With the
addition of GM, activation of Ras was inhibited at 3 mM nilotinib,
and of mTOR at 5 mM nilotinib. Decrease of phosphorylation of
AKT was seen at 20 mM nilotinib in GM. For both conditions,
decrease in phosphorylation of S6 ribomsomal protein was seen at
20 uM of nilotinib and levels of mTOR activity fluctuates as
nilotinib concentrations increases (Fig. 6a, b), (see discussion).
Activation of ERK1/2 was not inhibited by nilotinib to any
significant extent (data not shown).
Discussion
Vestibular schwannomas are benign tumors that grow slowly
and can often be managed with close observation. In instances of
large or growing and symptomatic tumors, surgery or radiosurgery
may be indicated, with potential complications and adverse effects.
In addition, for a distinct population of NF2 patients, surgery and
RT are not feasible and no additional therapy is currently
In PDGF-BB-supplemented media, the proportion of cells in G1-phase is
increased, and the proportion in S- and G2/M-phase decreased, at all
concentrations tested. Shown, mean of two replicate experiments. (C) In
GM, the proportion of cells in G1-phase is increased and the proportion
in G2/M decreased at $5 mM nilotinib. Shown, mean of two replicate
experiments.
doi:10.1371/journal.pone.0039412.g003
Figure 4. Nilotinib decreases the in vitro tumorigenicity of HEI-193 cells. Anchorage-independent growth in soft agar was inhibited in the
presence of nilotinib. (A) Visual assessment of agar plates shows qualitative decrease of colony formation by nilotinib. (B) The number of colonies was
reduced at $3 mM nilotinib in media containing PDGF-BB, and at $5 mM in GM. *denotes significant value (p,0.05). (C) The mean maximal colony
diameter was decreased by nilotinib at $3 mM in PDGF-BB media, and at $5 mM in GM. *denotes significant value (p,0.05).
doi:10.1371/journal.pone.0039412.g004
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and well-tolerated systemic therapy. Such therapy must have
minimal adverse effects over the long term, and can ideally be
administered at a low dose. The efficacy and utility of targeted
tyrosine kinase inhibition was demonstrated by imatinib in the
chronic treatment of CML driven by the BCR-ABL oncogene
[11,12]. Its sister compound nilotinib also targets BCR-ABL, as
well as c-KIT and PDGFRs, and is an appealing candidate for
management of VS due to its improved side-effect profile and
greater cell and tissue penetration.
Previous studies have demonstrated increased expression and
activation of RTKs, particularly PDGFR-b, in human schwan-
noma specimens and primary schwannoma cells [9,20]. Nilotinib
has been shown to reduce proliferation in primary schwannoma
cell cultures at concentrations significantly lower than imatinib
[20]. These are promising results, but examine PDGFR-b in
isolation; as patient-derived schwannomas express and activate
both PDGFR isoforms, the paradoxical decreased effect observed
at higher nilotinib concentration could be due to increased
activation of alternative receptors, such as PDGFR-a. Further-
more, the cell viability maintained at the very low nilotinib
concentration (0.5 mM) examined in this study may lead to
emergence of resistant mutants over time in a disease that requires
life-long treatment.
In contrast, in our study, we aimed to assess the role of PDGFR-
a in addition to PDGFR-b. We show that nilotinib administered
continuously at 3 mM for five days reduces viability of HEI-193
cells, which results from reduction of proliferation and increase of
cell cycle arrest and apoptosis. This prolonged treatment is critical
to achieve continuous inhibition of the receptors and to determine
whether resistant mutants will arise over time. In addition,
nilotinib reduces the number and size of colonies formed in
anchorage-independent growth assay. The observed reduction in
cell viability and clonogenicity results from nilotinib inhibiting the
PDGF-BB-mediated activation of PDGFR- a, PDGFR- b, AKT,
and mTOR, which it effects at a concentration below the mean
peak inhibitor concentration (4.27 mM) found in the serum of
patients treated for CML [18]. Thus, by increasing apoptosis and
reducing viability among cells of an established tumor, nilotinib
may be able to reduce tumor mass with tolerable systemic toxicity.
Figure 5. Nilotinib inhibition of HEI-193 cells decreases activation of PDGFR-a and PDGFR-b. HEI-193 cells inhibited with nilotinib and
stimulated with PDGF-BB or GM were lysed and analyzed by Western immunoblot using phophorylation-specific antibodies. Comparison was made
to total protein expression, as determined by immunoblotting using non-activation specific antibodies. Densitometry was used to evaluate fold-
change in phosphorylation, with values normalized to activation in the presence of vehicle control. **denotes significant (p,0.05) difference
compared to phosphorylation in vehicle control. (A) PDGF-BB activation of both PDGFR-a and PDGFR-b is abrogated in the presence of $3 mM
nilotinib. (B) GM-stimulated activation of PDGFR-b is inhibited by $3 mM nilotinib.
doi:10.1371/journal.pone.0039412.g005
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observed, but at slightly higher inhibitor concentration. This
difference in sensitivity to nilotinib is likely due to activation of
other receptors by factors released from the cells. As strong
activation of PDGFR-a is observed only when cells are grown in
PDGF-BB, and not in GM, the former better recapitulates the
growth environment of schwannomas, which exhibit increased
PDGFR-a expression and activation compared to Schwann cells
[10].
While the prolonged treatment used in the viability assays
demonstrated a sustained inhibition of PDGFR, a trend toward
decreased cell viability was observed as early as 24 hours into
treatment of cells cultured in PDGF-BB with 3 mM nilotinib, and
a significant decrease at 5 days. This correlated with a significant
increase in cell cycle arrest, as evidenced by accumulation of cells
in G1 phase, observed two days after start of treatment with 3 mM
nilotinib, as well as an increase in caspase-3/7 activity at 5 days of
treatment. A similar pattern was observed for cells cultured in GM
conditions (Fig. 1c).
The effect of nilotinib on receptor activation and tumorigenic
behavior correlate with its inhibition of PDGF-BB- and GM-
stimulated activation of downstream signaling mediators AKT and
mTOR. These findings are in keeping with established evidence of
the PI3K and mTOR pathways as critical regulators of
schwannoma growth [21]. Inhibition of PDGFR-a and -b occurs
at a low concentration of 3 mM which leads to inactivation of
downstream signaling but at different nilotinib concentrations.
While Ras activation is decreased at low nilotinib concentrations,
there is no significant effect on ERK1/2 phosphorylation, which is
in part explained by the presence of non-PDGFR-mediated means
of activating ERK1/2, as previously described in schwannomas
[9]. This supports the concept proposed by Ammoun et al. [20]
that nilotinib may be beneficial as one component in combina-
torial therapy. Phosphorylation of AKT is inhibited by 3 mM
niltonib in PDGF-BB-stimulated cells, but mTOR activity
fluctuates between 3 and 10 mM in both PDGF-BB and GM.
This might be due to the regulation of mTOR activity not only at
the PDGFR level but also by positive feedback mechanisms
downstream of the receptor, such as saturation of PI3K activity
[22]. Similarly, Ammoun et al. [20] showed that nilotinib at high
concentration (10 mM) completely loses effect in down-regulating
AKT and ERK1/2. Furthermore, decreased phosphorylation of
S6 ribosomal protein is seen only at high nilotinib concentration,
indicating the presence of alternative activation pathways further
downstream.
One limitation of this study is the use of a single cell line for the
investigations. The HEI-193 cell line was derived from a vestibular
schwannoma in a NF2 patient, and immortalized with human
papilloma E6–E7. A point mutation in NF2 results in a merlin
mutant that has attenuated, but not absent, tumor suppressor
activity [23]. Nevertheless, as HEI-193 cells have an expression
and activation profile for RTK targets of nilotinib similar to
human surgical VS specimens [10], it remains a valid model for
the functional experiments carried out here and elsewhere. Similar
to our work, Fraenzer et al. [24] stimulated HEI-193 cells with
PDGF to study the effects of NF2 restoration on PDGFR
degradation. Using the PDGF and GM stimulation strategy
previously shown [9,20,24], we established the in vivo PDGFR
receptor status in order to understand the mechanisms of nilotinib-
mediated effect.
In summary, these in vitro results support the anti-tumorigenic
activity of nilotinib in human vestibular schwannoma cells. These
preclinical results provide the basis to support testing Nilotinib as
potential biological therapy for growing VS. Given that there is
demonstrated safety and tolerability of Nilotinib through extensive
clinical experience with this compound in other tumor types, it
would be safe to proceed with clinical studies testing the efficacy of
Nilotinib in growing VS.
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